title: Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome.
abstract: The International Prognostic Scoring System (IPSS) is the most widely used tool for risk assessment and treatment decisions for myelodysplastic syndrome (MDS). Several new models have been proposed to identify a subset of lower-risk patients with MDS who are experiencing inferior than expected outcomes. We validated the Lower-Risk MD Anderson Risk Model (LR-MDAS) in 1288 lower-risk patients with MDS by the IPSS. On the basis of the LR-MDAS, 228 patients (17%) were in category 1, 730 patients (57%) were in category 2, 315 patients (25%) were in category 3, and 15 patients (1%) were in an unknown category. The median overall survival for the corresponding LR-MDAS categories was (1) 109 months (95% confidence interval [CI], 82-137), (2) 56 months (95% CI, 58-73), and (3) 29 months (95% CI, 24-35) (P < .005). Overall, 25% of patients were upstaged to category 3. LR-MDAS refined prognostic value among very low-, low-, and intermediate-risk Revised IPSS. The rate of acute myeloid leukemia transformation according to LR-MDAS was 15%, 18%, and 29% for categories 1, 2, and 3, respectively (P < .005). Our data validate the prognostic value of the LR-MDAS model, but the utility of it as a treatment decision tool should be studied prospectively.
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Rami
authors: R
authors: Komrokji
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: Hanadi.Ramadan@moffitt.org.
authors: Hanadi
authors: H
authors: Ramadan
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Najla
authors: N
authors: Al Ali
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Maria
authors: M
authors: Corrales-Yepez
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Ling
authors: L
authors: Zhang
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Eric
authors: E
authors: Padron
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Jeffrey
authors: J
authors: Lancet
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Alan
authors: A
authors: List
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000401:mortality*; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016019:Survival Analysis
keywords: IPSS; LR-MDAS; MDS; Prognosis; Risk models